title: Inhibitory effect of etodolac, a selective cyclooxygenase-2 inhibitor, on stomach carcinogenesis in Helicobacter pylori-infected Mongolian gerbils.
abstract: The effect of the selective COX-2 inhibitor, etodolac, on Helicobacter pylori (Hp)-associated stomach carcinogenesis was investigated in Mongolian gerbils (MGs). Hp-infected MGs were fed for 23 weeks with drinking water containing 10 ppm N-methyl-N-nitrosourea. They were then switched to distilled water and placed on a diet containing 5-30 mg/kg/day etodolac for 30 weeks. We found that etodolac dose-dependently inhibited the development of gastric cancer, and no cancer was detected at a dose of 30 mg/kg/day. Etodolac did not affect the extent of inflammatory cell infiltration or oxidative DNA damage, but it significantly inhibited mucosal cell proliferation and dose-dependently repressed the development of intestinal metaplasia in the stomachs of Hp-infected MGs. These results suggest that COX-2 is a key molecule in inflammation-mediated stomach carcinogenesis and that chemoprevention of stomach cancer should be possible by controlling COX-2 expression or activity.
authors: Second Department of Internal Medicine, Wakayama Medical University, Wakayama 641-0012, Japan.
authors: Hirohito
authors: H
authors: Magari
authors: Yasuhito
authors: Y
authors: Shimizu
authors: Ken-ichi
authors: K
authors: Inada
authors: Shotaro
authors: S
authors: Enomoto
authors: Tatsuji
authors: T
authors: Tomeki
authors: Kimihiko
authors: K
authors: Yanaoka
authors: Hideyuki
authors: H
authors: Tamai
authors: Kenji
authors: K
authors: Arii
authors: Hiroya
authors: H
authors: Nakata
authors: Masashi
authors: M
authors: Oka
authors: Hirotoshi
authors: H
authors: Utsunomiya
authors: Yutaka
authors: Y
authors: Tsutsumi
authors: Tetsuya
authors: T
authors: Tsukamoto
authors: Masae
authors: M
authors: Tatematsu
authors: Masao
authors: M
authors: Ichinose
mesh_terms: D000818:Animals; D016861:Cyclooxygenase Inhibitors / Q000008:administration & dosage*; D004305:Dose-Response Relationship, Drug; D017308:Etodolac / Q000008:administration & dosage*; D005849:Gerbillinae; D016481:Helicobacter Infections / Q000150:complications / Q000188:drug therapy*; D016480:Helicobacter pylori / Q000187:drug effects*; D008297:Male; D011230:Precancerous Conditions / Q000188:drug therapy* / Q000382:microbiology; D013274:Stomach Neoplasms / Q000209:etiology / Q000382:microbiology / Q000473:pathology* / Q000517:prevention & control*; D016896:Treatment Outcome
chemical_list: D016861:Cyclooxygenase Inhibitors; D017308:Etodolac